Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes
In this article NOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNT A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters New trial data suggests Novo Nordisk's weight loss drug Wegovy edges out rival treatments on heart condition risk reduction, in good news for the Danish pharma giant as it battles a spate of challenges in the key U.S. market. The company on Sunday said that continued use of its weight management drug semaglutide,
Read full story: Source